Perspectives of dendrimer-based nanoparticles in cancer therapy

Castro R.I.; Forero-Doria O.; Guzmán L.

dc.contributor.author	Castro R.I.
dc.contributor.author	Forero-Doria O.
dc.contributor.author	Guzmán L.
dc.date.accessioned	2020-09-02T22:14:19Z
dc.date.available	2020-09-02T22:14:19Z
dc.date.issued	2018
dc.identifier	10.1590/0001-3765201820170387
dc.identifier.citation	90, 2, 2331-2346
dc.identifier.issn	00013765
dc.identifier.uri	https://hdl.handle.net/20.500.12728/3955
dc.description	Currently, cancer is the second most common cause of death in the United States, exceeded only by heart disease. Chemotherapy traditionally suffers from a non-specific distribution, with only a small fraction of the drug reaching the tumor, in this sense, the use of dendrimers incorporating drugs non-covalently encapsulated inside the dendrimer or covalently conjugated have proven to be effectives against different cancer cell lines. However, at present the dendrimers used as drug-carriers still do not meet the necessary characteristic to be considered as an ideal dendrimer for drug delivery; high toxicity, bio-degradability, low toxicity, biodistribution characteristics, and favorable retention with appropriate specificity and bioavailability have not been fully covered by the current available dendrimers. However, the development and study of new dendrimers drug-carriers continues to be an important tool in the cancer therapy as they can be functionalized with varied ligands to reach the tumor tissue through the different body barriers in the body with minimal loss of activity in the bloodstream, have the ability to selectively kill tumor cells without affecting the normal cells and most important with a release mechanism controlling actively. Given the continuous efforts and research in this area of interest, we presented in this review the work done with a special emphasis on the development of dendrimers as a major tool in the combination with drugs, as a potential adjunctive agent in anticancer therapy. © 2018, Academia Brasileira de Ciencias. All rights reserved.
dc.language.iso	en
dc.publisher	Academia Brasileira de Ciencias
dc.subject	Cancer therapy
dc.subject	Dendrimers
dc.subject	Nanoparticles
dc.subject	Pharmacodynamics
dc.subject	antineoplastic agent
dc.subject	dendrimer
dc.subject	drug carrier
dc.subject	nanoparticle
dc.subject	animal
dc.subject	human
dc.subject	neoplasm
dc.subject	Animals
dc.subject	Antineoplastic Agents
dc.subject	Dendrimers
dc.subject	Drug Carriers
dc.subject	Humans
dc.subject	Nanoparticles
dc.subject	Neoplasms
dc.title	Perspectives of dendrimer-based nanoparticles in cancer therapy
dc.type	Article